Breast cancer | Prostate cancer | LAM | |
Host factors | |||
Younger age | + | - | + |
African–American | + | + | ? |
Tumour factors | |||
Stage | TNM | TNM | Lymphatic involvement? |
Histology score | Elston–Ellis | Gleason score | LAM histology score |
Lymphovascular involvement | + | + | + |
Receptor status | ER/PR/Her2 | - | ER/PR/Bcl2/TERT? |
Circulating tumour cells | + | ? | + |
Genetic profiling | + | - | ? |
Serum marker of response to therapy | - | Decreased PSA | Decreased VEGF-D |
LAM: Lymphangioleiomyomatosis; TNM: tumour, nodes, metastasis; ER: oestrogen receptor; PR: progesterone receptor; Her2: Human epidermal growth factor receptor-2; Bcl2: B-cell lymphoma-2; TERT: telomerase reverse transcriptase; PSA: prostate specific antigen; VEGF-D: vascular endothelial growth factor-D; +: predictor associated with condition; -: predictor not associated with condition; ?: insufficient evidence regarding association.